Advertisement

Comorbidity in Aging and Cancer

  • Erika E. RamsdaleEmail author
  • Jason Zittel
  • Diana Sarfati
Living reference work entry

Abstract

Comorbidity, the presence of coexisting diseases, is common in older adults with cancer. However, measurement of comorbidity is challenging due to its manifold presentation; numerous measures have been developed and validated, but there is no “gold standard” for comorbidity measurement in patients with cancer. However, a few tools have been developed specifically for quantification of comorbidity in older adults and/or patients with cancer. Comorbidity has complex interactions with cancer risk, prognosis, cancer treatment decisions, and tolerability of cancer treatment. For older adults in particular, comorbidity can imply “competing risks” for mortality and therefore a projected lack of benefit for anticancer therapies; on the other hand, comorbidity is not always associated with worse outcomes from these therapies. Comprehensive geriatric assessment (CGA) along with assessment of patients’ goals and overall life expectancy can assist with decision-making in older adults with cancer and comorbidity.

Keywords

Comorbidity Cancer 

References

  1. Ahern TP, Lash TL, Thwin SS, Silliman RA. Impact of acquired comorbidities on all-cause mortality rates among older breast cancer survivors. Med Care. 2009;47:73–9.PubMedPubMedCentralCrossRefGoogle Scholar
  2. Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:3675–86.CrossRefGoogle Scholar
  3. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol. 1996;156:127–32.PubMedCrossRefGoogle Scholar
  4. Alibhai SM, Breunis H, Timilshina N, et al. Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:5038–45.CrossRefGoogle Scholar
  5. American College of O-G. Practice bulletin no. 122: breast cancer screening. Obstet Gynecol. 2011;118:372–82.CrossRefGoogle Scholar
  6. Ash A, Porell F, Gruenberg L, Sawitz E, Beiser A. Adjusting medicare capitation payments using prior hospitalization data. Health Care Financ Rev. 1989;10:17–29.PubMedPubMedCentralGoogle Scholar
  7. Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:54–9.CrossRefGoogle Scholar
  8. Augschoell J, Kemmler G, Hamaker ME, Stauder R. PPT and VES-13 in elderly patients with cancer: evaluation in multidimensional geriatric assessment and prediction of survival. J Geriatr Oncol. 2014;5:415–21.PubMedCrossRefGoogle Scholar
  9. Baldwin LM, Klabunde CN, Green P, Barlow W, Wright G. In search of the perfect comorbidity measure for use with administrative claims data: does it exist? Med Care. 2006;44:745–53.PubMedCrossRefGoogle Scholar
  10. Bellera CA, Rainfray M, Mathoulin-Pelissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23:2166–72.PubMedCrossRefGoogle Scholar
  11. Billmeier SE, Ayanian JZ, He Y, Jaklitsch MT, Rogers SO. Predictors of nursing home admission, severe functional impairment, or death one year after surgery for non-small cell lung cancer. Ann Surg. 2013;257:555–63.PubMedCrossRefGoogle Scholar
  12. Blanco JA, Toste IS, Alvarez RF, Cuadrado GR, Gonzalvez AM, Martin IJ. Age, comorbidity, treatment decision and prognosis in lung cancer. Age Ageing. 2008;37:715–8.PubMedCrossRefGoogle Scholar
  13. Blustein J, Weiss LJ. The use of mammography by women aged 75 and older: factors related to health, functioning, and age. J Am Geriatr Soc. 1998;46:941–6.PubMedCrossRefGoogle Scholar
  14. Bouchardy C, Rapiti E, Fioretta G, et al. Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:3580–7.CrossRefGoogle Scholar
  15. Boulos DL, Groome PA, Brundage MD, et al. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent. Cancer. 2006;106:1804–14.PubMedCrossRefGoogle Scholar
  16. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294:716–24.PubMedCrossRefGoogle Scholar
  17. Bradley CJ, Dahman B, Anscher M. Prostate cancer treatment and survival: evidence for men with prevalent comorbid conditions. Med Care. 2014;52:482–9.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Braithwaite D, Moore DH, Satariano WA, et al. Prognostic impact of comorbidity among long-term breast cancer survivors: results from the LACE study. Cancer Epidemiol Biomark Prev. 2012;21:1115–25.CrossRefGoogle Scholar
  19. Brewer N, Borman B, Sarfati D, et al. Does comorbidity explain the ethnic inequalities in cervical cancer survival in New Zealand? A retrospective cohort study. BMC Cancer. 2011;11:132.PubMedPubMedCentralCrossRefGoogle Scholar
  20. Brunello A, Fontana A, Zafferri V, et al. Development of an oncological-multidimensional prognostic index (Onco-MPI) for mortality prediction in older cancer patients. J Cancer Res Clin Oncol. 2016;142:1069–77.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Bylow K, Hemmerich J, Mohile SG, Stadler WM, Sajid S, Dale W. Obese frailty, physical performance deficits, and falls in older men with biochemical recurrence of prostate cancer on androgen deprivation therapy: a case-control study. Urology. 2011;77:934–40.PubMedPubMedCentralCrossRefGoogle Scholar
  22. Cardia J, Calcada C, Pereira H. Treatment of lung cancer in the elderly: influence of comorbidity on toxicity and survival. Rep Pract Oncol Radiother. 2011;16:45–8.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA Guideline. J Urol. 2013;190:419–26.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Castro MA, Dedivitis RA, Ribeiro KC. Comorbidity measurement in patients with laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2007;69:146–52.PubMedCrossRefGoogle Scholar
  25. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services; 2017.Google Scholar
  26. Chang HJ, Chen PC, Yang CC, Su YC, Lee CC. Comparison of elixhauser and charlson methods for predicting oral cancer survival. Medicine (Baltimore). 2016;95:e2861.CrossRefGoogle Scholar
  27. Chao HH, Mayer T, Concato J, Rose MG, Uchio E, Kelly WK. Prostate cancer, comorbidity, and participation in randomized controlled trials of therapy. J Investig Med. 2010;58:566–8.PubMedCrossRefGoogle Scholar
  28. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRefGoogle Scholar
  29. Chen C, Sia I, Ma HM, et al. The synergistic effect of functional status and comorbidity burden on mortality: a 16-year survival analysis. PLoS One. 2014;9:e106248.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Cho H, Mariotto AB, Mann BS, Klabunde CN, Feuer EJ. Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence. Am J Epidemiol. 2013;178:339–49.PubMedPubMedCentralCrossRefGoogle Scholar
  31. Chu QD, Zhou M, Medeiros KL, Peddi P, Wu XC. Impact of CALGB 9343 trial and sociodemographic variation on patterns of adjuvant radiation therapy practice for elderly women (>/=70 Years) with Stage I, Estrogen receptor-positive breast cancer: analysis of the national cancer data base. Anticancer Res. 2017;37:5585–94.PubMedGoogle Scholar
  32. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care. 1995;33:783–95.PubMedCrossRefGoogle Scholar
  33. Colinet B, Jacot W, Bertrand D, et al. A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson’s index. Br J Cancer. 2005;93:1098–105.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Cook LS, Nelson HE, Cockburn M, Olson SH, Muller CY, Wiggins CL. Comorbidities and endometrial cancer survival in Hispanics and non-Hispanic whites. Cancer Causes Control. 2013;24:61–9.PubMedCrossRefGoogle Scholar
  35. de Glas NA, van de Water W, Engelhardt EG, et al. Validity of adjuvant! Online program in older patients with breast cancer: a population-based study. Lancet Oncol. 2014;15:722–9.PubMedCrossRefGoogle Scholar
  36. de Glas NA, Bastiaannet E, Engels CC, et al. Validity of the online PREDICT tool in older patients with breast cancer: a population-based study. Br J Cancer. 2016;114:395–400.PubMedPubMedCentralCrossRefGoogle Scholar
  37. Dehal A, Abbas A, Johna S. Comorbidity and outcomes after surgery among women with breast cancer: analysis of nationwide in-patient sample database. Breast Cancer Res Treat. 2013;139:469–76.PubMedCrossRefGoogle Scholar
  38. Denlinger CS, Engstrom PF. Colorectal cancer survivorship: movement matters. Cancer Prev Res (Phila). 2011;4:502–11.CrossRefGoogle Scholar
  39. Djunic I, Virijevic M, Novkovic A, et al. Comorbidity as a risk factor for overall survival and decision criteria for intensity of chemotherapy in elderly patients with acute myeloid leukemia. Med Oncol. 2012;29:1077–81.PubMedCrossRefGoogle Scholar
  40. Dobbins TA, Badgery-Parker T, Currow DC, Young JM. Assessing measures of comorbidity and functional status for risk adjustment to compare hospital performance for colorectal cancer surgery: a retrospective data-linkage study. BMC Med Inform Decis Mak. 2015;15:55.PubMedPubMedCentralCrossRefGoogle Scholar
  41. Draft Recommendation Statement: Prostate Cancer: Screening. U.S. Preventive Services Task Force. April 2017. https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementDraft/prostate-cancer-screening1
  42. Edwards BK, Noone AM, Mariotto AB, et al. Annual report to the nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290–314.PubMedCrossRefGoogle Scholar
  43. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.PubMedCrossRefGoogle Scholar
  44. ElSawy M, Storer BE, Pulsipher MA, et al. Multi-centre validation of the prognostic value of the haematopoietic cell transplantation- specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. Br J Haematol. 2015;170:574–83.PubMedPubMedCentralCrossRefGoogle Scholar
  45. Etzioni DA, El-Khoueiry AB, Beart RW Jr. Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review. Cancer. 2008;113: 3279–89.PubMedCrossRefGoogle Scholar
  46. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000;36:453–71.PubMedCrossRefGoogle Scholar
  47. Extermann M. Interaction between comorbidity and cancer. Cancer Control. 2007;14:13–22.PubMedCrossRefGoogle Scholar
  48. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:1824–31.CrossRefGoogle Scholar
  49. Extermann M, Overcash J, Lyman G, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16:1582–7.CrossRefGoogle Scholar
  50. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241–52.PubMedCrossRefGoogle Scholar
  51. Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118:3377–86.PubMedCrossRefGoogle Scholar
  52. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23:455–68.PubMedCrossRefGoogle Scholar
  53. Fillenbaum GG, Smyer MA. The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire. J Gerontol. 1981;36:428–34.PubMedCrossRefGoogle Scholar
  54. Fleming ST, Rastogi A, Dmitrienko A, Johnson KD. A comprehensive prognostic index to predict survival based on multiple comorbidities: a focus on breast cancer. Med Care. 1999;37:601–14.PubMedCrossRefGoogle Scholar
  55. Fleming ST, Pursley HG, Newman B, Pavlov D, Chen K. Comorbidity as a predictor of stage of illness for patients with breast cancer. Med Care. 2005;43:132–40.PubMedCrossRefGoogle Scholar
  56. Fortin M, Dionne J, Pinho G, Gignac J, Almirall J, Lapointe L. Randomized controlled trials: do they have external validity for patients with multiple comorbidities? Ann Fam Med. 2006;4:104–8.PubMedPubMedCentralCrossRefGoogle Scholar
  57. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl 1):S4–9.PubMedCrossRefGoogle Scholar
  58. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–56.PubMedCrossRefGoogle Scholar
  59. Froehner M, Koch R, Litz R, Heller A, Oehlschlaeger S, Wirth MP. Comparison of the American Society of Anesthesiologists Physical Status classification with the Charlson score as predictors of survival after radical prostatectomy. Urology. 2003;62:698–701.PubMedCrossRefGoogle Scholar
  60. Froehner M, Kellner AE, Koch R, Baretton GB, Hakenberg OW, Wirth MP. A combined index to classify prognostic comorbidity in candidates for radical prostatectomy. BMC Urol. 2014;14:28.PubMedPubMedCentralCrossRefGoogle Scholar
  61. Gallagher TK, McErlean S, O’Farrell A, et al. Incidence and risk factors of delirium in patients post pancreaticoduodenectomy. HPB (Oxford). 2014;16:864–9.CrossRefGoogle Scholar
  62. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674–85.PubMedPubMedCentralCrossRefGoogle Scholar
  63. Gonzalez EC, Ferrante JM, Van Durme DJ, Pal N, Roetzheim RG. Comorbid illness and the early detection of cancer. South Med J. 2001;94:913–20.PubMedCrossRefGoogle Scholar
  64. Gonzalez BD, Jim HS, Booth-Jones M, et al. Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:2021–7.CrossRefGoogle Scholar
  65. Greene-Schloesser D, Robbins ME. Radiation-induced cognitive impairment–from bench to bedside. Neuro-Oncology. 2012;14(Suppl 4):iv37–44.PubMedPubMedCentralCrossRefGoogle Scholar
  66. Greene-Schloesser D, Robbins ME, Peiffer AM, Shaw EG, Wheeler KT, Chan MD. Radiation-induced brain injury: a review. Front Oncol. 2012;2:73.PubMedPubMedCentralCrossRefGoogle Scholar
  67. Greenfield S, Apolone G, McNeil BJ, Cleary PD. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement. Med Care. 1993;31:141–54.PubMedCrossRefGoogle Scholar
  68. Greenfield S, Sullivan L, Dukes KA, Silliman R, D’Agostino R, Kaplan SH. Development and testing of a new measure of case mix for use in office practice. Med Care. 1995;33:AS47–55.PubMedGoogle Scholar
  69. Gronberg BH, Sundstrom S, Kaasa S, et al. Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer. 2010;46:2225–34.PubMedCrossRefGoogle Scholar
  70. Gross CP, McAvay GJ, Guo Z, Tinetti ME. The impact of chronic illnesses on the use and effectiveness of adjuvant chemotherapy for colon cancer. Cancer. 2007;109:2410–9.PubMedCrossRefGoogle Scholar
  71. Gurney J, Sarfati D, Stanley J. The impact of patient comorbidity on cancer stage at diagnosis. Br J Cancer. 2015;113:1375–80.PubMedPubMedCentralCrossRefGoogle Scholar
  72. Hall SF, Rochon PA, Streiner DL, Paszat LF, Groome PA, Rohland SL. Measuring comorbidity in patients with head and neck cancer. Laryngoscope. 2002;112:1988–96.PubMedCrossRefGoogle Scholar
  73. Hall WH, Jani AB, Ryu JK, Narayan S, Vijayakumar S. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis. 2005;8:22–30.PubMedCrossRefGoogle Scholar
  74. Hamstra DA, Stenmark MH, Ritter T, et al. Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85:1246–53.PubMedCrossRefGoogle Scholar
  75. Heflin MT, Oddone EZ, Pieper CF, Burchett BM, Cohen HJ. The effect of comorbid illness on receipt of cancer screening by older people. J Am Geriatr Soc. 2002;50:1651–8.PubMedCrossRefGoogle Scholar
  76. Hines RB, Chatla C, Bumpers HL, et al. Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:4339–45.CrossRefGoogle Scholar
  77. Holman CD, Preen DB, Baynham NJ, Finn JC, Semmens JB. A multipurpose comorbidity scoring system performed better than the Charlson index. J Clin Epidemiol. 2005;58:1006–14.PubMedCrossRefGoogle Scholar
  78. Houterman S, Janssen-Heijnen ML, Verheij CD, et al. Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. Br J Cancer. 2004;90:2332–7.PubMedPubMedCentralCrossRefGoogle Scholar
  79. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:2382–7.CrossRefGoogle Scholar
  80. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104:1998–2005.PubMedCrossRefGoogle Scholar
  81. Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol Off J Am Soc Clin Oncol. 2011a;29:3457–65.CrossRefGoogle Scholar
  82. Hurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol Off J Am Soc Clin Oncol. 2011b;29:1290–6.CrossRefGoogle Scholar
  83. Hurria A, Browner IS, Cohen HJ, et al. Senior adult oncology. J Natl Compr Cancer Netw. 2012;10:162–209.CrossRefGoogle Scholar
  84. Inouye SK, Westendorp RG, Saczynski JS. Delirium in elderly people. Lancet. 2014;383:911–22.PubMedCrossRefGoogle Scholar
  85. Jacot W, Colinet B, Bertrand D, et al. Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients. Ann Oncol. 2008;19:1458–64.PubMedCrossRefGoogle Scholar
  86. Janelsins MC, Heckler CE, Peppone LJ, et al. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: an analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol Off J Am Soc Clin Oncol. 2016;  https://doi.org/10.1200/JCO.2016.68.5826.PubMedCrossRefGoogle Scholar
  87. Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol. 2005;55:231–40.PubMedCrossRefGoogle Scholar
  88. Janssen-Heijnen ML, Lemmens VE, van den Borne BE, Biesma B, Oei SB, Coebergh JW. Negligible influence of comorbidity on prognosis of patients with small cell lung cancer: a population-based study in the Netherlands. Crit Rev Oncol Hematol. 2007;62:172–8.PubMedCrossRefGoogle Scholar
  89. Jehn CF, Boning L, Kroning H, Pezzutto A, Luftner D. Influence of comorbidity, age and performance status on treatment efficacy and safety of cetuximab plus irinotecan in irinotecan-refractory elderly patients with metastatic colorectal cancer. Eur J Cancer. 2014;50:1269–75.PubMedCrossRefGoogle Scholar
  90. Jorgensen TL, Teiblum S, Paludan M, et al. Significance of age and comorbidity on treatment modality, treatment adherence, and prognosis in elderly ovarian cancer patients. Gynecol Oncol. 2012;127:367–74.PubMedCrossRefGoogle Scholar
  91. Kanesvaran R, Li H, Koo KN, Poon D. Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:3620–7.CrossRefGoogle Scholar
  92. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis. 1974;27:387–404.PubMedCrossRefGoogle Scholar
  93. Keating NL, Landrum MB, Klabunde CN, et al. Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:2532–7.CrossRefGoogle Scholar
  94. Khrizman P, Niland JC, ter Veer A, et al. Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:30–8.CrossRefGoogle Scholar
  95. Kiefe CI, Funkhouser E, Fouad MN, May DS. Chronic disease as a barrier to breast and cervical cancer screening. J Gen Intern Med. 1998;13:357–65.PubMedPubMedCentralCrossRefGoogle Scholar
  96. Kim ES, Atlas J, Ison G, Ersek JL. Transforming clinical trial eligibility criteria to reflect practical clinical application. Am Soc Clin Oncol Educ Book. 2016;35:83–90.PubMedCrossRefGoogle Scholar
  97. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258–67.PubMedCrossRefGoogle Scholar
  98. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17:584–90.PubMedCrossRefGoogle Scholar
  99. Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121:4287–94.PubMedPubMedCentralCrossRefGoogle Scholar
  100. Korc-Grodzicki B, Root JC, Alici Y. Prevention of post-operative delirium in older patients with cancer undergoing surgery. J Geriatr Oncol. 2015;6:60–9.PubMedCrossRefGoogle Scholar
  101. Krzyzanowska MK, Regan MM, Powell M, Earle CC, Weeks JC. Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer. J Am Coll Surg. 2009;208:202–9.PubMedCrossRefGoogle Scholar
  102. Land LH, Dalton SO, Jensen MB, Ewertz M. Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990-2008. Breast Cancer Res Treat. 2012a;131:1013–20.PubMedCrossRefGoogle Scholar
  103. Land LH, Dalton SO, Jorgensen TL, Ewertz M. Comorbidity and survival after early breast cancer. A review. Crit Rev Oncol Hematol. 2012b;81:196–205.PubMedCrossRefGoogle Scholar
  104. Lash TL, Thwin SS, Horton NJ, Guadagnoli E, Silliman RA. Multiple informants: a new method to assess breast cancer patients’ comorbidity. Am J Epidemiol. 2003;157:249–57.PubMedCrossRefGoogle Scholar
  105. Lee SJ, Lindquist K, Segal MR, Covinsky KE. Development and validation of a prognostic index for 4-year mortality in older adults. JAMA. 2006;295:801–8.PubMedCrossRefGoogle Scholar
  106. Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010;7:18–27.PubMedCrossRefGoogle Scholar
  107. Lee L, Cheung WY, Atkinson E, Krzyzanowska MK. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:106–17.CrossRefGoogle Scholar
  108. Lee CC, Ho HC, Su YC, Chen PC, Yu CH, Yang CC. Comparison of different comorbidity measures for oral cancer patients with surgical intervention: a longitudinal study from a single cancer center. Auris Nasus Larynx. 2016;43:322–9.PubMedCrossRefGoogle Scholar
  109. Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S, Repelaer van Driel OJ, Coebergh JW. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg. 2005;92:615–23.PubMedCrossRefGoogle Scholar
  110. Lemmens VE, Janssen-Heijnen ML, Houterman S, et al. Which comorbid conditions predict complications after surgery for colorectal cancer? World J Surg. 2007;31:192–9.PubMedCrossRefGoogle Scholar
  111. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570–95.PubMedCrossRefGoogle Scholar
  112. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:1383–9.CrossRefGoogle Scholar
  113. Lieffers JR, Baracos VE, Winget M, Fassbender K. A comparison of Charlson and Elixhauser comorbidity measures to predict colorectal cancer survival using administrative health data. Cancer. 2011;117:1957–65.PubMedCrossRefGoogle Scholar
  114. Lin TL, Kuo MC, Shih LY, et al. The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. Ann Hematol. 2012;91:1383–91.PubMedCrossRefGoogle Scholar
  115. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16:622–6.PubMedCrossRefGoogle Scholar
  116. Litwin MS, Greenfield S, Elkin EP, Lubeck DP, Broering JM, Kaplan SH. Assessment of prognosis with the total illness burden index for prostate cancer: aiding clinicians in treatment choice. Cancer. 2007;109:1777–83.PubMedCrossRefGoogle Scholar
  117. LoConte NK, Smith M, Alberti D, et al. Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy. Cancer Chemother Pharmacol. 2010;65:775–80.PubMedCrossRefGoogle Scholar
  118. Louwman WJ, Aarts MJ, Houterman S, van Lenthe FJ, Coebergh JW, Janssen-Heijnen ML. A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status. Br J Cancer. 2010;103:1742–8.PubMedPubMedCentralCrossRefGoogle Scholar
  119. Magnusson C, Baron J, Persson I, et al. Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer. 1998;76:29–34.PubMedCrossRefGoogle Scholar
  120. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:6865–72.CrossRefGoogle Scholar
  121. Mandelblatt JS, Bierman AS, Gold K, et al. Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods. Health Serv Res. 2001;36:1085–107.PubMedPubMedCentralGoogle Scholar
  122. McBean AM, Yu X. The underuse of screening services among elderly women with diabetes. Diabetes Care. 2007;30:1466–72.PubMedCrossRefGoogle Scholar
  123. McGinty HL, Phillips KM, Jim HS, et al. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer. 2014;22:2271–80.PubMedPubMedCentralCrossRefGoogle Scholar
  124. Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2003;21:433–40.CrossRefGoogle Scholar
  125. Miller MD, Paradis CF, Houck PR, et al. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res. 1992;41:237–48.PubMedCrossRefGoogle Scholar
  126. Moe EL, Borsch C, Garg B, et al. Falls and frailty in prostate cancer survivors on androgen deprivation therapy. J Clin Oncol. 2016;34:134.CrossRefGoogle Scholar
  127. Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, Canin B, Cohen HJ, Holmes HM, Hopkins JO, Janelsins MC, Khorana AA, Klepin HD, Lichtman SM, Mustian KM, Tew WP, Hurria A. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36(22):2326-2347.  https://doi.org/10.1200/JCO.2018.78.8687. Epub 2018 May 21. PubMed PMID: 29782209; PubMed Central PMCID: PMC6063790.PubMedCrossRefGoogle Scholar
  128. Mohile SG, Fan L, Reeve E, et al. Association of cancer with geriatric syndromes in older Medicare beneficiaries. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:1458–64.CrossRefGoogle Scholar
  129. Mohile SG, Velarde C, Hurria A, et al. Geriatric assessment-guided care processes for older adults: a delphi consensus of geriatric oncology experts. J Natl Compr Cancer Netw. 2015;13:1120–30.CrossRefGoogle Scholar
  130. Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med. 2015;66:17–29.PubMedCrossRefGoogle Scholar
  131. Moyer VA, U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012a;156:880–91, W312PubMedCrossRefGoogle Scholar
  132. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012b;157:120–34.PubMedCrossRefGoogle Scholar
  133. Moyer VA, U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160:330–8.PubMedGoogle Scholar
  134. Munro AJ, Bentley AH. Deprivation, comorbidity and survival in a cohort of patients with colorectal cancer. Eur J Cancer Care (Engl). 2004;13:254–62.CrossRefGoogle Scholar
  135. Naeim A, Reuben D. Geriatric syndromes and assessment in older cancer patients. Oncology (Williston Park). 2001;15:1567–77, 80; discussion 81, 86, 91.Google Scholar
  136. Newschaffer CJ, Bush TL, Penberthy LT. Comorbidity measurement in elderly female breast cancer patients with administrative and medical records data. J Clin Epidemiol. 1997;50:725–33.PubMedCrossRefGoogle Scholar
  137. Newschaffer CJ, Bush TL, Penberthy LE, Bellantoni M, Helzlsour K, Diener-West M. Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. J Gerontol A Biol Sci Med Sci. 1998;53:M372–8.PubMedCrossRefGoogle Scholar
  138. Nightingale G, Hajjar E, Swartz K, Andrel-Sendecki J, Chapman A. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:1453–9.CrossRefGoogle Scholar
  139. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. JAMA. 2015;314:1599–614.PubMedPubMedCentralCrossRefGoogle Scholar
  140. Overcash JA, Beckstead J, Extermann M, Cobb S. The abbreviated comprehensive geriatric assessment (aCGA): a retrospective analysis. Crit Rev Oncol Hematol. 2005;54:129–36.PubMedCrossRefGoogle Scholar
  141. Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J. Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:214–9.CrossRefGoogle Scholar
  142. Parker ED, Folsom AR. Intentional weight loss and incidence of obesity-related cancers: the Iowa Women’s Health Study. Int J Obes Relat Metab Disord. 2003;27:1447–52.PubMedCrossRefGoogle Scholar
  143. Peters TT, van der Laan BF, Plaat BE, Wedman J, Langendijk JA, Halmos GB. The impact of comorbidity on treatment-related side effects in older patients with laryngeal cancer. Oral Oncol. 2011;47:56–61.PubMedCrossRefGoogle Scholar
  144. Piccirillo JF, Costas I. The impact of comorbidity on outcomes. ORL J Otorhinolaryngol Relat Spec. 2004;66:180–5.PubMedCrossRefGoogle Scholar
  145. Piccirillo JF, Lacy PD, Basu A, Spitznagel EL. Development of a new head and neck cancer-specific comorbidity index. Arch Otolaryngol Head Neck Surg. 2002;128:1172–9.PubMedCrossRefGoogle Scholar
  146. Piccirillo JF, Costas I, Claybour P, Borah A, Gorove L, Jeffe D. The measurement of comorbidity by cancer registries. J Registry Manag. 2003;30:8–14.Google Scholar
  147. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441–7.PubMedCrossRefGoogle Scholar
  148. Putt M, Long JA, Montagnet C, et al. Racial differences in the impact of comorbidities on survival among elderly men with prostate cancer. Med Care Res Rev. 2009;66:409–35.PubMedPubMedCentralCrossRefGoogle Scholar
  149. Raats JW, van Eijsden WA, Crolla RM, Steyerberg EW, van der Laan L. Risk Factors and Outcomes for Postoperative Delirium after Major Surgery in Elderly Patients. PLoS One. 2015;10:e0136071.PubMedPubMedCentralCrossRefGoogle Scholar
  150. Rabin BA, Gaglio B, Sanders T, et al. Predicting cancer prognosis using interactive online tools: a systematic review and implications for cancer care providers. Cancer Epidemiol Biomark Prev. 2013;22:1645–56.CrossRefGoogle Scholar
  151. Ramjaun A, Nassif MO, Krotneva S, Huang AR, Meguerditchian AN. Improved targeting of cancer care for older patients: a systematic review of the utility of comprehensive geriatric assessment. J Geriatr Oncol. 2013;4:271–81.PubMedCrossRefGoogle Scholar
  152. Ramsdale E, Sanoff H, Muss H. Approach to the older patient with stage II/III colorectal cancer: who should get curative-intent therapy? Am Soc Clin Oncol Educ Book. 2013;33:163–8.CrossRefGoogle Scholar
  153. Read WL, Tierney RM, Page NC, et al. Differential prognostic impact of comorbidity. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:3099–103.CrossRefGoogle Scholar
  154. Reeves KW, Faulkner K, Modugno F, et al. Body mass index and mortality among older breast cancer survivors in the Study of Osteoporotic Fractures. Cancer Epidemiol Biomark Prev. 2007;16:1468–73.CrossRefGoogle Scholar
  155. Reid BC, Alberg AJ, Klassen AC, Koch WM, Samet JM. The American Society of Anesthesiologists’ class as a comorbidity index in a cohort of head and neck cancer surgical patients. Head Neck. 2001;23:985–94.PubMedCrossRefGoogle Scholar
  156. Reid BC, Alberg AJ, Klassen AC, et al. A comparison of three comorbidity indexes in a head and neck cancer population. Oral Oncol. 2002;38:187–94.PubMedCrossRefGoogle Scholar
  157. Rex DK, Boland CR, Dominitz JA, et al. Colorectal Cancer Screening: recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2017;153:307–23.PubMedCrossRefGoogle Scholar
  158. Riechelmann RP, Moreira F, Smaletz O, Saad ED. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005;56:286–90.PubMedCrossRefGoogle Scholar
  159. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99:592–600.PubMedCrossRefGoogle Scholar
  160. Ring A. The influences of age and co-morbidities on treatment decisions for patients with HER2-positive early breast cancer. Crit Rev Oncol Hematol. 2010;76:127–32.PubMedCrossRefGoogle Scholar
  161. Sanabria A, Carvalho AL, Vartanian JG, Magrin J, Ikeda MK, Kowalski LP. Validation of the Washington University Head and Neck Comorbidity Index in a cohort of older patients. Arch Otolaryngol Head Neck Surg. 2008;134:603–7.PubMedCrossRefGoogle Scholar
  162. Sarfati D. Review of methods used to measure comorbidity in cancer populations: no gold standard exists. J Clin Epidemiol. 2012;65:924–33.PubMedCrossRefGoogle Scholar
  163. Sarfati D, Hill S, Blakely T, et al. The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study. BMC Cancer. 2009;9:116.PubMedPubMedCentralCrossRefGoogle Scholar
  164. Sarfati D, Blakely T, Pearce N. Measuring cancer survival in populations: relative survival vs cancer-specific survival. Int J Epidemiol. 2010;39:598–610.PubMedCrossRefGoogle Scholar
  165. Sarfati D, Gurney J, Stanley J, et al. Cancer-specific administrative data-based comorbidity indices provided valid alternative to Charlson and National Cancer Institute Indices. J Clin Epidemiol. 2014a;67:586–95.PubMedCrossRefGoogle Scholar
  166. Sarfati D, Gurney J, Stanley J, Lim BT, McSherry C. Development of a pharmacy-based comorbidity index for patients with cancer. Med Care. 2014b;52:586–93.PubMedCrossRefGoogle Scholar
  167. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147–72.PubMedPubMedCentralCrossRefGoogle Scholar
  168. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104–10.PubMedCrossRefGoogle Scholar
  169. Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:2036–8.CrossRefGoogle Scholar
  170. Schonberg MA, Davis RB, McCarthy EP, Marcantonio ER. Index to predict 5-year mortality of community-dwelling adults aged 65 and older using data from the National Health Interview Survey. J Gen Intern Med. 2009;24:1115–22.PubMedPubMedCentralCrossRefGoogle Scholar
  171. Schonberg MA, Li V, Marcantonio ER, Davis RB, McCarthy EP. Predicting mortality up to 14 years among community-dwelling adults aged 65 and older. J Am Geriatr Soc. 2017;65:1310–5.PubMedPubMedCentralCrossRefGoogle Scholar
  172. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93:850–7.PubMedCrossRefGoogle Scholar
  173. Shah-Khan F, Shah P. Loss of bladder sensation following taxane therapy. Chemotherapy. 2008;54:425–6.PubMedCrossRefGoogle Scholar
  174. Shahrokni A, Tin A, Downey RJ, et al. Electronic Rapid Fitness Assessment: a novel tool for Preoperative Evaluation of the Geriatric Oncology Patient. J Natl Compr Cancer Netw. 2017;15:172–9.CrossRefGoogle Scholar
  175. Shen Y, Hao Q, Zhou J, Dong B. The impact of frailty and sarcopenia on postoperative outcomes in older patients undergoing gastrectomy surgery: a systematic review and meta-analysis. BMC Geriatr. 2017;17:188.PubMedPubMedCentralCrossRefGoogle Scholar
  176. Silliman RA, Lash TL. Comparison of interview-based and medical-record based indices of comorbidity among breast cancer patients. Med Care. 1999;37:339–49.PubMedCrossRefGoogle Scholar
  177. Siu AL, U.S. Preventive Services Task Force. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164:279–96.PubMedCrossRefGoogle Scholar
  178. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:2758–65.CrossRefGoogle Scholar
  179. Soares M, Salluh JI, Ferreira CG, Luiz RR, Spector N, Rocco JR. Impact of two different comorbidity measures on the 6-month mortality of critically ill cancer patients. Intensive Care Med. 2005;31:408–15.PubMedCrossRefGoogle Scholar
  180. Sogaard M, Thomsen RW, Bossen KS, Sorensen HT, Norgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013;5:3–29.PubMedPubMedCentralCrossRefGoogle Scholar
  181. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–9.PubMedPubMedCentralCrossRefGoogle Scholar
  182. Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:3249–56.CrossRefGoogle Scholar
  183. Stairmand J, Signal L, Sarfati D, et al. Consideration of comorbidity in treatment decision making in multidisciplinary cancer team meetings: a systematic review. Ann Oncol. 2015;26:1325–32.PubMedCrossRefGoogle Scholar
  184. Takeuchi M, Takeuchi H, Fujisawa D, et al. Incidence and risk factors of postoperative delirium in patients with esophageal cancer. Ann Surg Oncol. 2012;19:3963–70.PubMedCrossRefGoogle Scholar
  185. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Impact of comorbidity on lung cancer survival. Int J Cancer. 2003;103:792–802.PubMedCrossRefGoogle Scholar
  186. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005;294:1765–72.PubMedCrossRefGoogle Scholar
  187. Taneja S, Mandayam S, Kayani ZZ, Kuo YF, Shahinian VB. Comparison of stage at diagnosis of cancer in patients who are on dialysis versus the general population. Clin J Am Soc Nephrol. 2007;2:1008–13.PubMedPubMedCentralCrossRefGoogle Scholar
  188. Terret C, Castel-Kremer E, Albrand G, Droz JP. Effects of comorbidity on screening and early diagnosis of cancer in elderly people. Lancet Oncol. 2009;10:80–7.PubMedCrossRefGoogle Scholar
  189. Tinetti ME, Inouye SK, Gill TM, Doucette JT. Shared risk factors for falls, incontinence, and functional dependence. Unifying the approach to geriatric syndromes. JAMA. 1995;273:1348–53.PubMedCrossRefGoogle Scholar
  190. Tomaszewski JJ, Uzzo RG, Kutikov A, et al. Assessing the burden of complications after surgery for clinically localized kidney cancer by age and comorbidity status. Urology. 2014;83:843–9.PubMedPubMedCentralCrossRefGoogle Scholar
  191. U.S. Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;315:2564–75.CrossRefGoogle Scholar
  192. van de Poll-Franse LV, Haak HR, Coebergh JW, Janssen-Heijnen ML, Lemmens VE. Disease-specific mortality among stage I-III colorectal cancer patients with diabetes: a large population-based analysis. Diabetologia. 2012;55:2163–72.PubMedPubMedCentralCrossRefGoogle Scholar
  193. van der Poel MW, Mulder WJ, Ossenkoppele GJ, et al. Factors that influence treatment decision-making in elderly DLBCL patients: a case vignette study. Ann Hematol. 2015;94:1373–9.PubMedPubMedCentralCrossRefGoogle Scholar
  194. van Gestel YR, Lemmens VE, de Hingh IH, et al. Influence of comorbidity and age on 1-, 2-, and 3-month postoperative mortality rates in gastrointestinal cancer patients. Ann Surg Oncol. 2013;20:371–80.PubMedCrossRefGoogle Scholar
  195. van Walraven C, Austin PC, Jennings A, Quan H, Forster AJ. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009;47:626–33.PubMedCrossRefGoogle Scholar
  196. Vickers MM, Powell ED, Asmis TR, et al. Comorbidity, age and overall survival in patients with advanced pancreatic cancer – results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. Eur J Cancer. 2012;48:1434–42.PubMedCrossRefGoogle Scholar
  197. Vigneri R. Diabetes: diabetes therapy and cancer risk. Nat Rev Endocrinol. 2009;5:651–2.PubMedCrossRefGoogle Scholar
  198. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16:1103–23.PubMedCrossRefGoogle Scholar
  199. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197–203.CrossRefGoogle Scholar
  200. Wallis CJD, Glaser A, Hu JC, et al. Survival and complications following surgery and radiation for localized prostate cancer: an international collaborative review. Eur Urol. 2017;71:417.CrossRefGoogle Scholar
  201. Walter LC, Covinsky KE. Cancer screening in elderly patients: a framework for individualized decision making. JAMA. 2001;285:2750–6.PubMedCrossRefGoogle Scholar
  202. Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:1447–55.CrossRefGoogle Scholar
  203. Weiner JP, Starfield BH, Steinwachs DM, Mumford LM. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care. 1991;29:452–72.PubMedCrossRefGoogle Scholar
  204. Wender R, Fontham ET, Barrera E Jr, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63:107–17.PubMedPubMedCentralCrossRefGoogle Scholar
  205. Williams GR, Mackenzie A, Magnuson A, et al. Comorbidity in older adults with cancer. J Geriatr Oncol. 2016a;7:249–57.PubMedCrossRefGoogle Scholar
  206. Williams AM, Zent CS, Janelsins MC. What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research. Br J Haematol. 2016b;174:835–46.PubMedPubMedCentralCrossRefGoogle Scholar
  207. Winters-Stone KM, Moe E, Graff JN, et al. Falls and frailty in prostate cancer survivors: current, past, and never users of androgen deprivation therapy. J Am Geriatr Soc. 2017;65:1414–9.PubMedPubMedCentralCrossRefGoogle Scholar
  208. Wishart GC, Azzato EM, Greenberg DC, et al. PREDICT: a new UK prognostic model that predicts survival following surgery for invasive breast cancer. Breast Cancer Res. 2010;12:R1.PubMedPubMedCentralCrossRefGoogle Scholar
  209. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70–98.PubMedCrossRefGoogle Scholar
  210. Wolin KY, Luly J, Sutcliffe S, Andriole GL, Kibel AS. Risk of urinary incontinence following prostatectomy: the role of physical activity and obesity. J Urol. 2010;183:629–33.PubMedCrossRefGoogle Scholar
  211. Yancik R, Havlik RJ, Wesley MN, et al. Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol. 1996;6:399–412.PubMedCrossRefGoogle Scholar
  212. Yasmeen S, Hubbard RA, Romano PS, et al. Risk of advanced-stage breast cancer among older women with comorbidities. Cancer Epidemiol Biomark Prev. 2012;21:1510–9.CrossRefGoogle Scholar
  213. Yasmeen S, Chlebowski RT, Xing G, Morris CR, Romano PS. Severity of comorbid conditions and early-stage breast cancer therapy: linked SEER-Medicare data from 1993 to 2005. Cancer Med. 2013;2:526–36.PubMedPubMedCentralCrossRefGoogle Scholar
  214. Zhang W, Ayanian JZ, Zaslavsky AM. Patient characteristics and hospital quality for colorectal cancer surgery. Int J Qual Health Care. 2007;19:11–20.PubMedCrossRefGoogle Scholar
  215. Zhu Y, Wang G, Liu S, et al. Risk factors for postoperative delirium in patients undergoing major head and neck cancer surgery: a meta-analysis. Jpn J Clin Oncol. 2017;47:505–11.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Erika E. Ramsdale
    • 1
    Email author
  • Jason Zittel
    • 1
  • Diana Sarfati
    • 2
  1. 1.School of Medicine and DentistryUniversity of Rochester Medical CenterRochesterUSA
  2. 2.University of OtagoWellingtonNew Zealand

Section editors and affiliations

  • William Dale
    • 1
  1. 1.Department of Supportive Care MedicineCity of Hope Duarte - Comprehensive Cancer CenterDuarteUSA

Personalised recommendations